2-OXAANDROSTAN-3-ONE, 17-HYDROXY-17-METHYL-, (5.ALPHA.,17.BETA.)-
HIV Wasting Syndrome
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Small moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the HIV Wasting Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
MEGESTROL ACETATE IMPURITY B Endo USA Inc., a Keenova Therapeutics Company | Phase 2 | BB |
Genotropin EMD Serono | Phase 3 | B |
TESTOSTERONE ENANTATE | Phase 2 | B |
Thalidomide | Phase 2 | B |
TESTOSTERONE UNDECYLATE National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | B |
View all 11 →
Same molecule, other indications
2-OXAANDROSTAN-3-ONE, 17-HYDROXY-17-METHYL-, (5.ALPHA.,17.BETA.)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →